EU approval for GlaxoSmithKline and Human Genome's Benlysta; Slowing Advair sales in USA
There was good news for UK pharma giant GlaxoSmithKline (LSE: GSK) and US partner Human Genome Sciences (Nasdaq: HGSI) yesterday, when the European Commission granted marketing authorization for Benlysta (belimumab), the first new drug for lupus approved in over 50 year, which was also approved in the USA earlier this year (The Pharma Letter March 10) and in Canada this week.
Benlysta was cleared in the European Union as an add-on therapy in adult patients with active autoantibody-positive systemic lupus erythematosus (SLE), with a high degree of disease activity (eg, positive anti-dsDNA and low complement), despite standard therapy.
Could achieve global sales of $5 billion in 2020
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze